Study of a targeted pill for BRCA-linked ovarian cancer
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests an experimental pill called DAT-2645 for patients with ovarian cancer that has a BRCA mutation or HRD. It's designed for people who have already tried other treatments, and it works by targeting a specific weakness in the cancer cells.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have ovarian cancer that has been confirmed by a biopsy or cytology test.
- You have either a BRCA1/2 gene mutation or a tumor with HRD (a specific kind of DNA repair problem).
- You have already tried standard treatments and they stopped working, or you couldn't tolerate them.
- You have had no more than 5 lines of previous cancer treatment.
- You have at least one tumor that can be measured on a scan.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests an experimental pill (DAT-2645) for people with advanced or metastatic solid tumors that have DNA repair problems, such as BRCA gene mutations. The drug targets a repair mechanism that these cancer cells need, potentially slowing or stopping their growth.
This study tests a new combination of two investigational drugs for patients with advanced ovarian, fallopian tube, or primary peritoneal cancer that has a BRCA gene mutation. The goal is to see if the combination is safe and effective, and it might offer a new treatment option for your type of cancer.
This study tests a new form of a drug similar to olaparib (Lynparza) in people with BRCA-mutated ovarian cancer. It looks at how the drug works in the body and checks for safety, to see if the new formulation is as effective and safe as the current one.
This trial is testing a new drug called DM5167 for people whose advanced solid tumors have a BRCA1 or BRCA2 gene mutation. The goal is to see if the drug can shrink tumors or slow their growth.
This study tests a new oral drug, DSB2455, for people with advanced breast, prostate, ovarian, or pancreatic cancers that have certain gene changes. It aims to see if the drug is safe and whether it helps shrink or control the cancer.
This trial tests a new drug called raludotatug deruxtecan (with or without bevacizumab) for people with ovarian cancer that has grown despite PARP inhibitor maintenance treatment. The goal is to see if this drug can shrink tumors or slow the cancer's growth.
Hear when a new Advanced or Metastatic Ovarian Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.